Point32Health Rebounds to $86 Million Q1 Profit After Restricting GLP-1 Coverage

1 articles · Updated · The Boston Globe · Jul 23

$86 million in Q1 2026 operating income marked a sharp turnaround for Point32Health from a $39 million loss a year earlier after it limited coverage of GLP-1 weight-loss drugs.
Patrick Gilligan said the insurer had badly underestimated how many patients would be prescribed GLP-1s for weight loss, turning the benefit into an affordability problem for individuals and employer plans.
Point32Health also tightened administrative spending and expanded utilization and care management programs, including prior authorizations, to contain medical costs.
Gilligan said the insurer still does not expect a full-year operating gain in 2026, calling it a bridge year as the company aims to return to modest profitability.
The pressure extends beyond GLP-1s: Gilligan cited post-pandemic pent-up care, rising specialty-drug costs and the end of some Massachusetts Health Connector subsidies, which reduced membership across the market.

Sources

Left100%

Point32Health cut GLP-1 coverage and finances improved—but will tighter drug rules save healthcare costs or just shift them to patients later?

If GLP-1 limits helped Point32Health rebound, are obesity drugs becoming the next major test of what insurance can still afford?

As gene therapies and weight-loss drugs soar, how should insurers decide which breakthrough treatments are worth covering—and for whom?

1 total

Left100%